Late Wednesday, the US Food and Drug Administration said it has granted accelerated approved for Tabrecta (capmatinib; INC280) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
Tabrecta, from Swiss pharma giant Novartis (NOVN: VX), is the first FDA-approved therapy to treat NSCLC with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping). “This patient population now has an option for a targeted therapy, which they didn’t have prior today,” commented Dr Richard Pazdur, director of the FDA’s Office of Oncologic Diseases.
This approval fills a long-recognized and urgent need among METex14 patients who have not had a treatment option approved to specifically target the driver of their lung cancer. Tabrecta is approved for first-line and previously treated patients, regardless of prior treatment type, and is expected to be available to patients in the coming days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze